Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Nov 2016

Meletath Silviya K, Pavlick Dean, Brennan Tim, Hamilton Roy, Chmielecki Juliann, Elvin Julia A, Palma Norma, Ross Jeffrey S, Miller Vincent A, Stephens Philip J, Snipes George, Rajaram Veena, Ali Siraj M, Melguizo-Gavilanes Isaac

Abstract excerpt

BACKGROUND: Gangliogliomas are slow-growing, low-grade central nervous system tumors affecting children and young adults. However, some patients will experience tumor recurrence and/or malignant progression. This article reports on the clinical history, molecular findings, and treatment response in a patient with BRAF V600-mutated high-grade glioma arising from ganglioglioma. METHODS: Hematoxylin-eosin staining...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Ganglioglioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Imidazoles

Share to Neoplasm Grading

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Young Adult

Source

Identifiers

PMID: 27799506
DOI: 10.6004/jnccn.2016.0145

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.PMID 27799506Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.Semantic proximity Read ↗

Impact of tissue-agnostic approvals on management of primary brain tumors.Semantic proximity Read ↗

Significant response to targeted therapy for Cervico-Medullary pediatric low grade glial tumors with BRAF V600E mutationSemantic proximity Read ↗

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma.Semantic proximity Read ↗

The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.Semantic proximity Read ↗

A Review of Recurrent Meningiomas with Prolonged Response to Cabozantinib, an Oral Multitarget Tyrosine Kinase InhibitorSemantic proximity Read ↗

Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal TumorsSemantic proximity Read ↗

A Review of Recurrent Meningiomas with Prolonged Response to Cabozantinib, an Oral Multitarget Tyrosine Kinase InhibitorSemantic proximity Read ↗

Practice-Changing Abstracts From the 2016 Society for Neuro-Oncology Annual Scientific Meeting.Semantic proximity Read ↗

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

BRAF inhibition efficacy in drug-refractory epilepsySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.